|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A retrospective chart review was conducted of patients with HER2-positive early-stage breast cancer receiving non-anthracycline trastuzumab-based therapy between January 2010 and June 2014.
|
28710537 |
2017 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Five-year local control rates after breast-conserving surgery, APBI, and appropriate systemic therapy are excellent for luminal, HER2, and basal phenotypes of early-stage breast cancer; however, further study of receptor subtype effect on risk stratification in early-stage breast cancer is needed.
|
27666436 |
2017 |
|
Early-Stage Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, in ER+/Her2- early stage breast cancer patients gene-expression profile use was associated with a consistent proportion of patients receiving chemotherapy despite an adjusted guideline-based recommendation to administer chemotherapy.
|
27062369 |
2016 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
|
26971372 |
2016 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although trastuzumab-based therapy is considered standard of care among patients with HER2-positive early-stage breast cancer, approximately 28% of these patients did not receive HER2-targeted therapy.
|
26395563 |
2016 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with HER2- positive early stage breast cancer receiving adjuvant trastuzumab were investigated retrospectively.
|
25743846 |
2015 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Decision analysis was used to estimate the number of patients with early-stage breast cancer (EBC) whose HER2 status was misclassified in 2012.
|
26091608 |
2015 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 100 patients with ER+, human epidermal growth factor receptor 2-negative EBC, and node-negative (pN0) disease or micrometastases in up to 3 lymph nodes (pN1mi) were enrolled.
|
26112003 |
2015 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2-targeted therapies, usually in combination with chemotherapy, are the standard of care, improving the cure rate in early-stage breast cancer and lengthening survival in the advanced setting.
|
24335887 |
2014 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared to non-Hispanic whites, Hispanic women with hormone-sensitive, HER2-negative early-stage breast cancer had a higher Proliferation Axis Score.
|
25254601 |
2014 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2 ordering using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) was abstracted from the charts of 314 patients with early-stage breast cancer.
|
24614047 |
2014 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since 2005, 12 months of adjuvant trastuzumab has been the standard treatment for patients with HER2-positive early-stage breast cancer.
|
23764181 |
2013 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In HER2-positive early stage breast cancer patients, PTEN loss was not associated with the disease-free survival (DFS) rate of trastuzumab-based adjuvant treatment (HR = 1.096, 95% CI: 0.706-1.700, P = 0.684).
|
23574264 |
2013 |
|
Early-Stage Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Eligible patients were aged 18-75 years; had Eastern Cooperative Oncology Group performance status of 1 or less; HER2-amplified early stage breast cancer; operable, histologically confirmed, invasive carcinoma of the breast; adequate tumour specimen available for FISH analysis of TOP2A status; and adequate haematological, renal, hepatic, and cardiac function.
|
24007746 |
2013 |
|
Early-Stage Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Retrospective cohort study of central HER2 test documentation in early-stage BC patients diagnosed in 2006-2007.
|
23379747 |
2013 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Guiding decision-making on adjuvant chemotherapy using the 21-gene assay was projected to improve survival, quality-adjusted life expectancy, and be cost saving vs the current standard of care women with ER+, HER2- early-stage breast cancer.
|
22966753 |
2013 |
|
Early-Stage Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Is obesity always a risk factor for all breast cancer patients? c-erbB2 expression is significantly lower in obese patients with early stage breast cancer.
|
22855166 |
2012 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Simultaneous copy number gains of NUPR1 and ERBB2 predicting poor prognosis in early-stage breast cancer.
|
22938721 |
2012 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The introduction of the assay into Japanese practice of ER+, LN-, HER2- ESBC treatment by including it to Japan's social health insurance benefit package has a reasonable chance to be judged as cost-effective and may be justified as an efficient deployment of finite health care resources.
|
22315134 |
2012 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.
|
22333602 |
2012 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Before 2005, these individuals had an increased risk of recurrence and death, but since then their outcomes have substantially improved with the adoption in most countries of adjuvant trastuzumab as a standard component of therapy for HER2-positive early-stage breast cancer.
|
22410709 |
2012 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Women with operable early-stage breast cancer were enrolled in a multicenter study of neoadjuvant therapy for four 21-day cycles with capecitabine 825 mg/m(2) plus docetaxel 75 mg/m(2) if human epidermal growth factor receptor 2 (HER2)-negative, and additionally, a standard trastuzumab dose if HER2-positive.
|
21373875 |
2012 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Trials to define, refine and optimize the use of the two approved HER2-targeted agents (trastuzumab and lapatinib) in patients with HER2-positive early stage breast cancer are ongoing.
|
22124364 |
2011 |
|
Early-Stage Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Despite advances with adjuvant endocrine treatment for hormone receptor-positive tumors and with trastuzumab for HER2-positive disease, overall, over 50% of women with early-stage breast cancer experience recurrence and die of the disease.
|
20735306 |
2010 |
|
Early-Stage Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
|
19620488 |
2009 |